论文部分内容阅读
目的：明确血清CA19-9测定对小胰腺癌诊断的意义。方法：通过对86例胰腺癌患者血清CA19-9的检测，并对其中18例肿瘤直径≤2cm(小胰腺癌)患者进行B超、CT、MRI及ERCP检测。结果：结果表明小胰腺癌患者血清CA19-9的阳性率为61.1%，平均值为140.5u/ml，病理显示CA19-9阳性多见于病灶有转移的小胰腺癌病人。血清CA19-9的阳性与小胰腺癌的病程，部位无关。结论：CA19-9检测有助于对手术疗效的评价与术后随访的监测。MRI、ERCP对小胰腺癌诊断阳性率明显高于B超、CT。联合应用血清CA19-9、MRI、ERCP可达到早期诊断小胰腺癌的目的，而早期手术可降低死亡率，改善预后。
Objective: To determine the significance of serum CA19-9 determination in the diagnosis of small pancreatic cancer. METHODS: Serum CA19-9 was detected in 86 patients with pancreatic cancer and 18 patients with tumor diameter ≤2cm (small pancreatic cancer) were examined by ultrasound, CT, MRI, and ERCP. Results: The results showed that the positive rate of serum CA19-9 was 61.1% in patients with small pancreatic cancer, with an average of 140.5u/ml. The pathology showed that CA19-9 positive was more common in small pancreatic cancer patients with metastases. The positive serum CA19-9 had nothing to do with the course and location of small pancreatic cancer. Conclusion: The detection of CA19-9 is helpful to evaluate the efficacy of surgery and follow-up monitoring. The positive rate of MRI and ERCP in diagnosis of small pancreatic cancer was significantly higher than that of B-ultrasonography and CT. Combined use of serum CA19-9, MRI, and ERCP can achieve early diagnosis of small pancreatic cancer, and early surgery can reduce mortality and improve prognosis.